| Original language | English |
|---|---|
| Pages (from-to) | 330-332 |
| Number of pages | 3 |
| Journal | Psychiatry and clinical neurosciences |
| Volume | 74 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 01-05-2020 |
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Vortioxetine vs placebo in major depressive disorder : A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan. / Kishi, Taro; Sakuma, Kenji; Okuya, Makoto; Matsuda, Yuki; Iwata, Nakao.
In: Psychiatry and clinical neurosciences, Vol. 74, No. 5, 01.05.2020, p. 330-332.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Vortioxetine vs placebo in major depressive disorder
T2 - A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan
AU - Kishi, Taro
AU - Sakuma, Kenji
AU - Okuya, Makoto
AU - Matsuda, Yuki
AU - Iwata, Nakao
N1 - Funding Information: We would like to thank Takeda Pharmaceutical Company Limited (Tokyo, Japan ?103-8668) for confirming the number of Japan phase 3 trials of vortioxetine. Funding Information: Drs Kishi, Sakuma, Okuya, Matsuda, and Iwata declare that they have no direct conflicts of interest relevant to this study. No grant support or other sources of funding were used to conduct this study or prepare this manuscript. Dr Kishi has received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Kyowa, Otsuka, Pfizer, Meiji, MSD, Sumitomo Pharmaceuticals (Suzhou), Yoshitomi, and Tanabe‐Mitsubishi and has received a Health Labour Sciences Research Grant, Grant‐in‐Aid for Scientific Research (C), and a Fujita Health University School of Medicine research grant. Dr Sakuma has received speaker's honoraria from Otsuka and Meiji. Dr Okuya has received speaker's honoraria from Meiji. Dr Matsuda has received speaker's honoraria from Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Otsuka, Tanabe‐Mitsubishi, and Pfizer and has received a grant‐in‐aid for Young Scientists (B). Dr Iwata has received speaker's honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has had research grants from Dainippon Sumitomo, Eisai, Daiichi Sankyo, GlaxoSmithKline, Meiji, and Otsuka. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
UR - http://www.scopus.com/inward/record.url?scp=85082950886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082950886&partnerID=8YFLogxK
U2 - 10.1111/pcn.13001
DO - 10.1111/pcn.13001
M3 - Letter
C2 - 32175646
AN - SCOPUS:85082950886
VL - 74
SP - 330
EP - 332
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
IS - 5
ER -